TY - JOUR T1 - 2022-RA-796-ESGO Preoperative neutrophil lymphocyte ratio in ascites as a prognostic factor in epithelial ovarian cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - A263 LP - A263 DO - 10.1136/ijgc-2022-ESGO.561 VL - 32 IS - Suppl 2 AU - Jung Hyun Park AU - Min Jin Jeong AU - Chan Joo Kim AU - Yong Seok Lee Y1 - 2022/10/01 UR - http://ijgc.bmj.com/content/32/Suppl_2/A263.2.abstract N2 - Introduction/Background We investigated the clinical impact of NLR as a prognostic factor in malignant ascites in advanced ovarian cancer.Methodology We retrospectively reviewed all of the patients who were diagnosed with advanced epithelial ovarian cancer and who presented with ascites. To maintain the quality of the study, only 92 patients with malignant cells in the ascites were included. Patients with clinically active infection in the time of paracentesis is excluded. If multiple times of paracentesis was done, we used initial result. Curves of DFS and OS were calculated using the Kaplan-Meier method, and univariate and multivariate analyses of various prognostic factors were performed using a Cox proportional hazard regression model.Results In a univariate analysis, high serum NLR, malignant ascitic NLR were associated with shorter overall survival (p < 0.001, p < 0.001, respectively); moreover, age, Eastern Cooperative Oncology Group performance status (ECOG PS), histology, stage, hemoglobin level, albumin level, and calcium level were significant prognostic factors. A multivariable analysis confirmed that ECOG PS (p < 0.001), histology (p = 0.001), serum NLR (p=o.oo7) and malignant ascitic NLR (p = 0.012) were independent predictors of overall survival.Conclusion Our findings showed that an elevated preoperative NLR in serum and malignant ascites were associated with poor clinical outcome in ovarian cancer patients. Although further studies are required to generalize our results, this information will benefit clinicians and patients in determining the most appropriate therapy for patients with malignant ascites. ER -